I-Mab to Participate in the H.C. Wainwright “HCW@Home” Series

Core Insights - I-Mab is participating in the H.C. Wainwright "HCW@Home" Series on June 17, 2025, focusing on its pipeline and developments in precision immuno-oncology [1][3] - The discussion will highlight the Claudin 18.2 landscape as a therapeutic target for gastric cancers, particularly emphasizing the bispecific antibody givastomig [2][4] Company Overview - I-Mab is a U.S.-based global biotech company specializing in precision immuno-oncology agents for cancer treatment [4] - The company's leading candidate, givastomig, is a bispecific antibody targeting Claudin 18.2 and 4-1BB, designed for Claudin 18.2-positive gastric cancers [4] - Givastomig is currently in Phase 1 trials, showing strong tumor-binding properties and anti-tumor activity while minimizing common toxicities associated with other 4-1BB agents [4] Conference Details - The H.C. Wainwright "HCW@Home with I-Mab" event will be a fireside chat moderated by Dr. Andres Maldonado, featuring I-Mab's management team [3] - The event is scheduled for June 17, 2025, from 10:00 AM to 11:00 AM ET, and will be accessible for 90 days post-event on I-Mab's website [3]